{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:23:09Z","timestamp":1788258189343,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T23:39:42Z","timestamp":1739835582000},"page":"1253-1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort"],"prefix":"10.1016","volume":"8","author":[{"given":"Michael","family":"Baboudjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Leni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oderda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Uleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Redondo","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Benard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.01.009_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2025.01.009_b0015","first-page":"135","article-title":"Using active surveillance for Gleason 7 (3+4) prostate cancer: a narrative review","volume":"18","author":"Bernardino","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.01.009_b0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.juro.2017.03.123","article-title":"Intermediate-term outcomes for men with very low\/low and intermediate\/high risk prostate cancer managed by active surveillance","volume":"198","author":"Nyame","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.01.009_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29760","article-title":"Trends in active surveillance for men with intermediate-risk prostate cancer","volume":"7","author":"Diven","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.01.009_b0035","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2025.01.009_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging-Reporting and Data System: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pros.23255","article-title":"Number of unfavorable intermediate-risk factors predicts pathologic upstaging and prostate cancer-specific mortality following radical prostatectomy: results from the SEARCH database","volume":"77","author":"Zumsteg","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.01.009_b0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5489\/cuaj.6328","article-title":"The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: results from a large, population-based cohort","volume":"14","author":"Richard","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.01.009_b0060","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0065","article-title":"Active surveillance of low-grade prostate cancer using the SurACaP criteria: a multi-institutional series with a median follow-up of 10 years","volume":"34","author":"Leclercq","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0070","doi-asserted-by":"crossref","unstructured":"Bangma C, Doan P, Zhu L, et al. Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.07.003.","DOI":"10.1016\/j.euo.2024.07.003"},{"key":"10.1016\/j.euo.2025.01.009_b0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0080","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.3390\/cancers14153558","article-title":"Adverse pathological findings at radical prostatectomy following active surveillance: results from the Movember GAP3 cohort","volume":"14","author":"Marenghi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.01.009_b0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euo.2023.11.011","article-title":"The impact of delayed radical prostatectomy on recurrence outcomes after initial active surveillance: results from a large institutional cohort","volume":"7","author":"Shee","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.01.009_b0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2013.01.019","article-title":"Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance","volume":"190","author":"Satkunasivam","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.011","article-title":"Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer","volume":"68","author":"Filippou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/JU.0000000000001089","article-title":"Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5489\/cuaj.2806","article-title":"Active surveillance for the management of localized prostate cancer: guideline recommendations","volume":"9","author":"Morash","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.01.009_b0110","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.009_b0115","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-023-04353-8","article-title":"Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach","volume":"41","author":"Baboudjian","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.01.009_b0120","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41391-023-00693-z","article-title":"MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients","volume":"27","author":"Baboudjian","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.01.009_b0125","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:35:31Z","timestamp":1766511331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125000276"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}